相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study
Masaki Yoshida et al.
BJU INTERNATIONAL (2020)
Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial
Henry D. Mitcheson et al.
EUROPEAN UROLOGY (2019)
Efficacy of novel β3-adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post-hoc analysis of a randomized, double-blind, placebo-controlled phase 3 study
Masaki Yoshida et al.
INTERNATIONAL JOURNAL OF UROLOGY (2019)
Effects of the combination of vibegron and imidafenacin on bladder function in urethane-anesthetized rats
Takanobu Yamazaki et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2019)
Vibegron, a Novel Potent and Selective beta(3)-Adrenoreceptor Agonist, for the Treatment of Patients with Overactive Bladder: A Randomized, Double-blind, Placebo-controlled Phase 3 Study
Masaki Yoshida et al.
EUROPEAN UROLOGY (2018)
Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis
Con Kelleher et al.
EUROPEAN UROLOGY (2018)
Long-term safety and efficacy of the novel β3-adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: A phase III prospective study
Masaki Yoshida et al.
INTERNATIONAL JOURNAL OF UROLOGY (2018)
Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder
J. Di Salvo et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
Combination therapy with β3-adrenoceptor agonists and muscarinic acetylcholine receptor antagonists: Efficacy in rats with bladder overactivity
Akira Furuta et al.
INTERNATIONAL JOURNAL OF UROLOGY (2016)
Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder
Scott D. Edmondson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Mirabegron in overactive bladder patients: efficacy review and update on drug safety
Katherine Warren et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2016)
Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony)
Paul Abrams et al.
EUROPEAN UROLOGY (2015)
Cumulative Use of Strong Anticholinergics and Incident Dementia A Prospective Cohort Study
Shelly L. Gray et al.
JAMA INTERNAL MEDICINE (2015)
Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence
Emilio Sacco et al.
EXPERT OPINION ON DRUG DISCOVERY (2014)
What do we know and not know about mirabegron, a novel β3 agonist, in the treatment of overactive bladder?
Romain Caremel et al.
INTERNATIONAL UROGYNECOLOGY JOURNAL (2014)
Nebivolol induces, via β3 adrenergic receptor, lipolysis, uncoupling protein 1, and reduction of lipid droplet size in human adipocytes
Marica Bordicchia et al.
JOURNAL OF HYPERTENSION (2014)
Mucosa of human detrusor impairs contraction and β-adrenoceptor-mediated relaxation
Stefan Propping et al.
BJU INTERNATIONAL (2013)
Effects of Mirabegron, a Novel β3-Adrenoceptor Agonist, on Primary Bladder Afferent Activity and Bladder Microcontractions in Rats Compared With the Effects of Oxybutynin
Naoki Aizawa et al.
EUROPEAN UROLOGY (2012)
The impact of anticholinergic burden in Alzheimer's Dementia-the Laser-AD study
Chris Fox et al.
AGE AND AGEING (2011)
Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction
Debra E. Irwin et al.
BJU INTERNATIONAL (2011)
Comparative Analysis of the Effects of Antimuscarinic Agents on Bladder Functions in Both Nonhuman Primates and Rodents
Hiroshi Nagabukuro et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Urothelial Beta-3 Adrenergic Receptors in the Rat Bladder
F. Aura Kullmann et al.
NEUROUROLOGY AND URODYNAMICS (2011)
β-Adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder
Brian J. Limberg et al.
CELL AND TISSUE RESEARCH (2010)
The beta(3)-Adrenoceptor Mediates the Inhibitory Effects of beta-Adrenoceptor Agonists Via the Urothelium in Pig Bladder Dome
Koichi Masunaga et al.
NEUROUROLOGY AND URODYNAMICS (2010)
A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder
Yukio Homma et al.
INTERNATIONAL JOURNAL OF UROLOGY (2009)
The β3-adrenoceptor as a therapeutic target: Current perspectives
Maria Grazia Ursino et al.
PHARMACOLOGICAL RESEARCH (2009)
Dual use of bladder anticholinergics and cholinesterase inhibitors: Long-term functional and cognitive outcomes
Kaycee M. Sink et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2008)
Expression and functional role of β-adrenoceptors in the human urinary bladder urothelium
Atsushi Otsuka et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2008)
Neuronally released acetylcholine acts on the M2 muscarinic receptor to oppose the relaxant effect of isoproterenol on cholinergic contractions in mouse urinary bladder
Frederick J. Ehlert et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Increased relaxant action of forskolin and isoproterenol against muscarinic agonist-induced contractions in smooth muscle from M2 receptor knockout mice
M Matsui et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
分享论文
